Scotia Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Scotia Capital’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-40,634	Closed	-$135K	–	815
2016 Q1	$135K	Sell	40,634 -90,682	-69%	-$283K	﹤0.01%	643
2015 Q4	$650K	Hold	131,316	–	–	0.01%	505
2015 Q3	$662K	Buy	131,316 +5,331	+4%	+$30.5K	0.02%	480
2015 Q2	$797K	Sell	125,985 -6,160	-5%	-$41.3K	0.02%	435
2015 Q1	$930K	Buy	132,145 +2,927	+2%	+$21.2K	0.02%	319
2014 Q4	$995K	Sell	129,218 -2,508	-2%	-$19.8K	0.03%	298
2014 Q3	$983K	Buy	131,726 +9,497	+8%	+$88.2K	0.02%	306
2014 Q2	$1.18M	Buy	122,229 +5,389	+5%	+$48K	0.03%	280
2014 Q1	$970K	Buy	116,840 +15,991	+16%	+$137K	0.02%	304
2013 Q4	$851K	Buy	100,849 +9,720	+11%	+$81.9K	0.02%	293
2013 Q3	$727K	Buy	91,129 +23,927	+36%	+$192K	0.02%	293
2013 Q2	$518K	Buy	+67,202	New	+$524K	0.02%	288

Other funds holding PDLI

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Emerald Acquisition Seattle, Washington $51.8B AUM

Scotia Capital's PDLI Position: Q2 2016 in Review

Scotia Capital sold out of PDL BioPharma, Inc. (PDLI) in Q2 2016, closing a stake of 40,634 shares — an estimated $135K sold.

Scotia Capital first reported a position in PDLI in Q2 2013 and held it in 12 quarters. The position peaked at $1.18M in Q2 2014. 201 funds tracked by Wall St. Rank hold PDLI as of Q2 2016.

Scotia Capital reported no remaining PDL BioPharma, Inc. position as of Q2 2016 after selling out during the quarter.
Scotia Capital sold 40,634 PDL BioPharma, Inc. shares in Q2 2016, an estimated $135K.
Scotia Capital first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 12 quarters.
Scotia Capital's PDL BioPharma, Inc. position peaked at $1.18M in Q2 2014.
201 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2016.

Based on Scotia Capital's 13F filing for Q2 2016, filed 11 Aug 2016.